A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
Clinical trial NCT06210490 · RECRUITING
Trial details
- NCT number
- NCT06210490
- Sponsor
- Peking University First Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-20
- Primary completion
- 2028-05-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.